TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glove-loaded Foley's Catheter Tamponade to Reducing Blood Loss During Cesarean Delivery for Complete Placenta Previa: a Randomized Controlled Trial
Brief Summary: Objective: To investigate the effect of A glove-loaded Foley's catheter tamponade versus stepwise uterine devascularization on blood loss during cesarean section (CS) in patients with complete placenta previa.


Options:
A: Arm Label: Amr Maneuver; Type: EXPERIMENTAL; Interventions: Procedure: Amr maneuver | Arm Label: Active management alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Amr maneuver; Assigned to Arm(s): Amr Maneuver
B: Arm Label: stepwise uterine devascularization; Type: ACTIVE_COMPARATOR; Interventions: Procedure: stepwise uterine devascularization | Arm Label: A glove-loaded Foley's catheter; Type: EXPERIMENTAL; Interventions: Procedure: A glove-loaded Foley's catheter tamponade | Intervention Type: PROCEDURE; Name: A glove-loaded Foley's catheter tamponade; Assigned to Arm(s): A glove-loaded Foley's catheter | Intervention Type: PROCEDURE; Name: stepwise uterine devascularization; Assigned to Arm(s): stepwise uterine devascularization
C: Arm Label: B-Lynch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: B-Lynch | Arm Label: Bakri balloon; Type: ACTIVE_COMPARATOR; Interventions: Procedure: BALLOON INSERTION | Intervention Type: PROCEDURE; Name: B-Lynch; Assigned to Arm(s): B-Lynch | Intervention Type: PROCEDURE; Name: BALLOON INSERTION; Assigned to Arm(s): Bakri balloon
D: Arm Label: Early Belfort-Dildy balloon device; Type: EXPERIMENTAL; Interventions: Device: Early Belfort-Dildy Balloon | Arm Label: Late Belfort-Dildy balloon device; Type: OTHER; Interventions: Device: Late Belfort-Dildy balloon | Intervention Type: DEVICE; Name: Early Belfort-Dildy Balloon; Assigned to Arm(s): Early Belfort-Dildy balloon device | Intervention Type: DEVICE; Name: Late Belfort-Dildy balloon; Assigned to Arm(s): Late Belfort-Dildy balloon device

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Brief Summary: This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.


Options:
A: Arm Label: Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Baricitinib Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Addenda Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Open-Label Addenda Baricitinib High Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Placebo
B: Arm Label: 4 Milligram (mg) Baricitinib; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: 2 mg Baricitinib; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 4 mg Baricitinib Maximum Extended Enrollment (MEE); Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: 2 mg Baricitinib MEE; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib | Arm Label: Placebo MEE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): 2 mg Baricitinib, 2 mg Baricitinib MEE, 4 Milligram (mg) Baricitinib, 4 mg Baricitinib Maximum Extended Enrollment (MEE) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 mg Baricitinib, 4 Milligram (mg) Baricitinib, 4 mg Baricitinib Maximum Extended Enrollment (MEE), Placebo, Placebo MEE
C: Arm Label: Phototherapeutic; Type: EXPERIMENTAL; Interventions: Radiation: ultraviolet A (UVA) | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone Acetonide | Intervention Type: RADIATION; Name: ultraviolet A (UVA); Assigned to Arm(s): Phototherapeutic | Intervention Type: DRUG; Name: Triamcinolone Acetonide; Assigned to Arm(s): Conventional therapy
D: Arm Label: Hydrocortisone 1%; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone 1% | Arm Label: Clobetasol Propionate 0.05%; Type: EXPERIMENTAL; Interventions: Drug: Clobetasol Propionate 0.05% | Intervention Type: DRUG; Name: Hydrocortisone 1%; Assigned to Arm(s): Hydrocortisone 1% | Intervention Type: DRUG; Name: Clobetasol Propionate 0.05%; Assigned to Arm(s): Clobetasol Propionate 0.05%

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
B: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab
C: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
D: Arm Label: Active Treatment (10 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (10 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Etanercept Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Etanercept Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept Placebo | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Tildrakizumab Placebo; Assigned to Arm(s): Etanercept 50 mg, Placebo | Intervention Type: DRUG; Name: Etanercept Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
C: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab
D: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 70 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 70 mg SC | Arm Label: 280 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 280 mg SC | Arm Label: 210 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg SC | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 70 mg SC; Assigned to Arm(s): 70 mg SC | Intervention Type: DRUG; Name: 210 mg SC; Assigned to Arm(s): 210 mg SC | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC | Intervention Type: DRUG; Name: 280 mg SC; Assigned to Arm(s): 280 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Weight Loss Induced by Daily Time-Restricted Feeding Versus Daily Caloric Restriction in Women With Overweight and Obesity
Brief Summary: The aim of the study is to determine if time-restricted feeding (TRF) is an effective dietary strategy to weight loss after 8 weeks intervention. TRF will be compared with an intervention without restriction in time for feeding. Both strategies will be with caloric restriction.


Options:
A: Arm Label: Time-Restricted Feeding (early in the day eating); Type: EXPERIMENTAL; Interventions: Other: Time-Restricted Feeding | Arm Label: Grazing; Type: PLACEBO_COMPARATOR; Interventions: Other: Grazing | Intervention Type: OTHER; Name: Time-Restricted Feeding; Assigned to Arm(s): Time-Restricted Feeding (early in the day eating) | Intervention Type: OTHER; Name: Grazing; Assigned to Arm(s): Grazing
B: Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Arm Label: Mediterranean diet; Type: EXPERIMENTAL; Interventions: Other: Mediterranean diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): Mediterranean diet | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
C: Arm Label: Caloric restriction only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caloric restriction only | Arm Label: Caloric restriction plus TRF morning; Type: EXPERIMENTAL; Interventions: Behavioral: Caloric restriction plus TRF morning | Arm Label: Caloric restriction plus TRF night; Type: EXPERIMENTAL; Interventions: Behavioral: Caloric restriction plus TRF night | Intervention Type: BEHAVIORAL; Name: Caloric restriction only; Assigned to Arm(s): Caloric restriction only | Intervention Type: BEHAVIORAL; Name: Caloric restriction plus TRF morning; Assigned to Arm(s): Caloric restriction plus TRF morning | Intervention Type: BEHAVIORAL; Name: Caloric restriction plus TRF night; Assigned to Arm(s): Caloric restriction plus TRF night
D: Arm Label: Experimental Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restrictive Feeding, Behavioral: Traditional Eating Pattern | Arm Label: Experimental Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restrictive Feeding, Behavioral: Traditional Eating Pattern | Intervention Type: BEHAVIORAL; Name: Time Restrictive Feeding; Assigned to Arm(s): Experimental Group 1, Experimental Group 2 | Intervention Type: BEHAVIORAL; Name: Traditional Eating Pattern; Assigned to Arm(s): Experimental Group 1, Experimental Group 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigating the Role of Early Low-dose Aspirin in Diabetes: A Phase III Multicentre Double-blinded Placebo-controlled Randomised Trial of Low-dose Aspirin Initiated in the First Trimester of Diabetes Pregnancy
Brief Summary: To investigate the effect of aspirin therapy initiated in the first trimester of pregnancy in women with pregestational type I or type II diabetes on a composite clinical measure of placental dysfunction (preeclampsia, preterm birth less than 34 weeks, birthweight below the 10th centile or perinatal mortality).


Options:
A: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Control Arm
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Aspirin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin group
D: Arm Label: Routine low-dose aspirin; Type: EXPERIMENTAL; Interventions: Drug: Low dose aspirin | Arm Label: No aspirin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Test-indicated low-dose aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): Routine low-dose aspirin, Test-indicated low-dose aspirin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Dietary Carbohydrate Manipulation on All Major Aspects of Energy Balance: A 12-week Randomised Controlled Trial
Brief Summary: This study will investigate how dietary sugar and carbohydrates influence metabolism and health across a 12-week period, with a focus on physical activity. One third of participants will eat a diet with typical amounts of sugar and carbohydrate, one third of participants will eat a diet with sugar intake restricted, and the final third of participants will eat a diet where both sugar and total carbohydrates are restricted and replaced with fat.


Options:
A: Arm Label: AARP; Type: N/A; Interventions: N/A
B: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
C: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
D: Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet | Arm Label: LOW SUG; Type: EXPERIMENTAL; Interventions: Other: Diet | Arm Label: LOW CHO; Type: EXPERIMENTAL; Interventions: Other: Diet | Intervention Type: OTHER; Name: Diet; Assigned to Arm(s): CONTROL, LOW CHO, LOW SUG

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact Evaluation of Maternal Health Information Messaging in India
Brief Summary: British Broadcasting Corporation (BBC) Media Action is presently implementing two large scale mobile health (mHealth) initiatives in India: Kilkari and Mobile Academy. Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old. Mobile Academy (MA) is an Interactive Voice Response (IVR) in-service audio training course for Accredited social health activists (ASHAs) in India designed to refresh their knowledge of life-saving preventative health behaviors and improve their interpersonal communications skills. Both programs were initiated in Bihar in 2012, and have been scaled widely in a number of states with support from Ministry of Health and Family Welfare (MOHFW) at the national level, National Health Missions (NHM) at the state level, and an alliance of donors (Gates Foundation, USAID, Barr Foundation, and UK Department for International Development (UKAid)).

The Johns Hopkins School of Public Health, Oxford Policy Management, and University of Cape Town are supporting BBC Media Action and the Ministry of Health and Family Welfare (MOHFW) are conducting an external evaluation of both Kilkari and Mobile Academy (MA). The evaluation spans through April 2020.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Quit4Baby, Behavioral: Text4Baby | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Text4Baby | Intervention Type: BEHAVIORAL; Name: Quit4Baby; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Text4Baby; Assigned to Arm(s): Control, Intervention
B: Arm Label: Kilkari; Type: EXPERIMENTAL; Interventions: Other: Kilkari | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Kilkari; Assigned to Arm(s): Kilkari
C: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention
D: Arm Label: Reminder module (SMS and Phone call); Type: EXPERIMENTAL; Interventions: Behavioral: Reminder module (SMS and Phone call) | Arm Label: Photovoice; Type: EXPERIMENTAL; Interventions: Behavioral: Photovoice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder module (SMS and Phone call); Assigned to Arm(s): Reminder module (SMS and Phone call) | Intervention Type: BEHAVIORAL; Name: Photovoice; Assigned to Arm(s): Photovoice

Answer: B